Second Dupixent® (dupilumab) Section 3 Eosinophilic Esophagitis Trial to Display Vital Illness Enhancements, Underscoring Position of Kind 2 Irritation in This Advanced Illness

TARRYTOWN, N.Y. and PARIS, Oct. 25, 2021 /PRNewswire/ —  Dupixent 300 mg weekly considerably improved the flexibility to swallow and diminished eosinophils within the esophagus in comparison with placebo, reinforcing optimistic outcomes from first Section 3 trial Eosinophilic esophagitis is a progressive illness that damages the esophagus and impairs the flexibility to swallow; 90% of … Read more

Menarini Group et Radius Health annoncent des résultats positifs de l’essai de phase 3 EMERALD évaluant l’Elacestrant chez les personnes ayant un cancer du sein

L’étude a été conçue pour évaluer l’élacestrant en monothérapie par rapport au traitement de référence (SoC) pour le traitement du cancer du sein avancé ou métastatique ER+/HER2-. Il y avait deux critères d’évaluation principaux : la survie sans progression (SSP) dans la population globale et la SSP chez les patientes dont les tumeurs présentaient des mutations … Read more

Innovent Announces ORIENT-31, a Phase 3 Study of Sintilimab in Patients with EGFR-Mutated Nonsquamous Non-Small Cell Lung Cancer with Prior EGFR-TKI Treatment, Has Met Primary Endpoint

[ad_1] SAN FRANCISCO and SUZHOU, China, Oct. 17, 2021 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, today announced that the sintilimab ORIENT-31 study has met its prespecified primary endpoint of progression-free survival … Read more

Ionis’ partner Biogen provides update on tofersen Phase 3 VALOR study in SOD1-ALS

[ad_1] CARLSBAD, Calif., Oct. 17, 2021 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) partner Biogen today announced topline results from its placebo-controlled pivotal Phase 3 VALOR study of tofersen (BIIB067), an investigational antisense medicine being evaluated for people with superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS). While tofersen did not meet the primary endpoint of … Read more

Les données de la phase II du vaccin COVID-19 de Medigen examinées et publiées dans The Lancet Respiratory Medicine

[ad_1] TAIPEI, 16 octobre 2021 /PRNewswire/ — The Lancet Respiratory Medicine, l’une des revues médicales à comité de lecture les plus connues au monde, a publié les Medigen Vaccine Biologics données de l’essai clinique de phase 2 du vaccin MVC-COV1901 qui démontrent des profils d’immunogénicité et de sécurité prometteurs. La source internationale de référence en matière de … Read more

Akeso is Rapidly Advancing The Phase II Clinical Trial of IL-4R Monoclonal Antibody (AK120) for the Treatment of Atopic Dermatitis and Asthma

[ad_1] HONG KONG, Oct. 15, 2021 /PRNewswire/ — Akeso, Inc. (the Company, 9926.HK) announces that the Company’s self-developed innovative drug candidate, IL-4R monoclonal antibody (AK120), was approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration of the People’s Republic of China to initiate a phase II clinical trial for the … Read more

UNION therapeutics announces enrollment of first patient in the OSIRIS Phase 2a study of oral orismilast for the treatment of mild to severe hidradenitis suppurativa

[ad_1] HELLERUP, Denmark, Oct. 14, 2021 /PRNewswire/ — UNION therapeutics A/S, a privately-held, multi-asset, clinical stage, pharmaceutical company focused on immunology and infectious diseases, today announced the enrollment of the first patient in OSIRIS, a Phase 2, open-label, proof of concept study of an oral tablet formulation of orismilast in adult patients with mild, moderate, and … Read more

REGENXBIO Presents Positive Initial Data from Phase II ALTITUDE™ Trial of RGX-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery at American Society of Retina Specialists Annual Meeting

[ad_1] ROCKVILLE, Md., Oct. 9, 2021 /PRNewswire/ — Suprachoroidal delivery of RGX-314 well tolerated in 15 patients in Cohort 1 with no drug-related serious adverse events No intraocular inflammation observed Positive interim data update from Cohort 1 at three months after one-time treatment of RGX-314 33% of patients demonstrated a ≥2 step improvement from baseline … Read more